RCVS CEO Lizzie Lockett said: "I am so proud of our performance in the Great Place to Work Awards and the efforts of everyone at the College, and especially our HR team, who have been tirelessly and creatively striving to make the College a wonderful place to work.
"Consistently being placed in the top 50 Great Places to Work is also a testament to the sustained hard work all of our employees and the important part they play in creating a supportive, interesting and good-humoured workplace.
"We are a service-led organisation and we want to make sure that we give our best to the veterinary professions and the general public. If our team enjoys the work, and the workplace, that will improve the service we are able to offer and, ultimately, benefit animal health and welfare."
Available for download now, the MobiVet Veterinary Formulary App is designed to make drug calculations and prescribing faster, easier and safer. It contains dose rate and interval data for over 250 drugs commonly used in small animal practice.
Searchable by drug name or trade names, with species-specific dosing information, the app calculates doses based on the patient type, weight, or body surface area as appropriate. MobiVet also provides a checklist of known relevant drug interactions for each medication, to prevent prescribing errors.
Stuart says an iOS version is in production.
To download the Android version, visit: https://play.google.com/store/apps/details?id=com.project.user.drug_formulary&hl=en
Cortotic contains hydrocortisone aceponate (HCA), a diester glucocorticosteroid to reduce inflammation.
In a clinical field study, published in Veterinary Dermatology, Cortotic was shown to be as effective in treating acute otitis as a fixed-combination product containing a corticosteroid, an antibiotic and an antifungal, with an equivalent improvement of clinical and cytological scores1.
A secondary reduction of bacterial and yeast overgrowth was demonstrated and a concomitant treatment with an antimicrobial was unnecessary.
The product was shown to provide rapid relief from clinical signs, pruritus and pain1.
Virbac says the lipophilic nature of the HCA diester provides enhanced penetration into the skin, a reservoir effect and low plasma availability for high local activity with reduced systemic secondary effects2.
Chris Newark, Product Manager at Virbac said: "With Cortotic we’re excited to offer clinicians the ability to reduce antimicrobial usage when treating otitis externa in dogs, whilst offering the same efficacy as a fixed-combination product.
"The product’s easy administration also makes it an attractive choice for pet owners with 94% of owners stating that they would choose to use Cortotic again3".
Cortotic is presented in an ear spray device with atraumatic cannula, which delivers a fine mist spray for even application.
Dosing is 2 pumps per application, whatever the dog’s size, once a day for 7-14 days.
References
Working in collaboration with researchers at University of Texas, Southwestern (UTSW) Medical Center, the team has succeeded in using gene editing techniques on dogs to restore the expression of the dystrophin protein that is absent in DMD patients’ muscles to levels that could be life changing.
DMD is the most common, fatal, genetic disease that affects children. The same disorder also occurs in many dog breeds. It is caused by mutations in the gene that encodes dystrophin, a crucial protein that helps protect muscle fibres and the heart when they contract. Patients with the disease produce effectively no dystrophin protein, so their muscles and heart become damaged during contraction, leading to inability to walk, skeletal deformities, breathing problems and heart failure. Patients with DMD have a life expectancy that does not go far beyond their twenties.
Researchers say that this preliminary research, published in Science, demonstrates an approach that could lead to an effective, in principle one-time treatment for DMD for the most common genetic mutations affecting human patients. Through a single intravenous injection, researchers have been able to modify the dystrophin gene in many muscles of the body, including the heart, with the result that some muscles now had almost the normal amounts of dystrophin protein.
The team, led by Eric Olson, Ph.D., professor and chair of the Department of Molecular Biology at UTSW Medical Center and founder and chief science advisor of Exonics Therapeutics, and Richard Piercy, Ph.D., MRCVS, Professor of Comparative Neuromuscular Disease at the RVC, identified a naturally-occurring mutation in the dystrophin gene in a dog brought to the RVC’s Small Animal Referral Hospital.
Working now with relatives of this first dog, the combined group has used a technique called ‘SingleCut CRISPR gene editing’, where the researchers target a specific region of the subject’s own DNA. Harmless viruses encoding the gene-editing protein CRISPR/Cas9 were used to express the enzyme in muscle to cut the dogs’ own DNA at a precise location in the dystrophin gene through use of a molecular guide. The body’s own processes then repair the cut, which results in removing the negative effects of the existing mutation.
The researchers have demonstrated that dogs treated in this way had restored ability to produce large amounts of the dystrophin protein in their muscles and heart, and in the dog with the highest dose, cardiac muscles were found to have restored dystrophin protein to up to 92% of normal amounts after the single treatment.
The team believes this is the first time that this form of gene editing therapy has been conducted after birth in an animal larger than a rodent. With further longer-term research, efficacy and safety testing, it is hoped that this breakthrough will have human application. This treatment may be a significant step toward developing a gene editing therapy to repair genetic mutations for DMD, as well as a range of diseases caused by genetic mutations.
Richard Piercy, Professor of Comparative Neuromuscular Disease at the RVC, said: "Researchers have been looking for an effective and durable treatment for Duchenne muscular dystrophy for many years. This SingleCut gene editing approach, pioneered by Dr. Eric Olson’s group, has the potential to be a one-time treatment that could restore dystrophin protein. It is hugely exciting that through a single intravenous injection we’ve been able successfully to modify the dogs’ own DNA so they start generating dystrophin protein again. There is more work to be done, but with this exciting breakthrough, we feel we are a significant step closer to finding an effective treatment.
"A great many genetic diseases affect humans, dogs and other species - many, like DMD - with tragic consequences and this form of gene editing treatment might well be applicable in many of them. We’re hopeful that we’re paving the way for future research into treating some of the most serious genetic conditions that affect us today."
The Stablelab hand-held reader detects and quantifies the biomarker Serum Amyloid A (SAA), an acute phase protein produced by the liver that increases rapidly and dramatically in response to inflammation.
Zoetis says that by measuring SAA, vets can assess the severity of an infection more quickly, often before clinical symptoms start, and are able to monitor the horse’s response over the course of treatment.1
Zoetis vet Wendy Talbot said: “Zoetis is committed to providing vets and horse owners with the most effective health products to better predict, prevent, detect and treat equine disease.
“The Stablelab test kit enables convenient, off-site testing for quick and accurate detection of a reliable indicator of infection in horses.
“Point-of-care testing is one of the fastest-growing areas of diagnostics and this test is rapidly becoming a standard of care in equine practice. SAA testing will help vets to quickly determine an appropriate course of intervention, positively impacting case outcomes.”
For more information, visit: www.stablelab.com. To place an order, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 (option 3).
Reference
Creature Comforts will be using the cash both to open the clinics and build a proprietary app which will give owners seamless 24/7 access to veterinary care, whilst allowing vets to work more flexibly and more often from home.
VetSurgeon.org caught up with Russell Welsh (pictured), co-founder of the new business alongside Daniel Attia.
Russell said: "During the pandemic, there was a recognition that employers needed to do more to attract and retain veterinary staff, and so there has been a move towards more flexible working and better employment packages.
"The problem is that we then saw a massive increase in the number of pets, and the profession is struggling to meet demand.
"On top of that, the corporatisation of the profession has meant that both staff and owners often feel less connected with each other.
"We think the answer lies in independent practices making better use of technology to reduce the workload on veterinary staff whilst creating a better, seamless, more personal experience for pet owners.
"There are of course companies offering online consultations, but they tend to be stand alone services, or belong to corporate groups.
"What we're doing differently is developing our own system so that we don't lose control of any stage in the client journey and can make sure the quality of care, after care and service is consistently high.
"We'll also be putting together a share option scheme, so our employees will really feel a proper sense of ownership."
https://www.creaturecomforts.co.uk
Dechra Veterinary Products has relaunched Oxyglobin after concluding an exclusive agreement to supply the product across the UK and Republic of Ireland.
Oxyglobin is used to stabilise anaemic dogs until the underlying condition can be controlled and the animal's body can produce its own new red blood cells.
Dechra says the treatment, which is now available in both 125ml bags and individual 60ml transfusion bags, maintains tissue oxygenation even when there is severe stenosis of blood vessels. It has a viscosity which is more than water but less than blood for ease of flow through vessels, and also increases circulatory volume.
Dechra Veterinary Products Brand Manager, Carol Morgan, said: "Veterinary professionals have been waiting for Oxyglobin to come back onto the market for some time and we're delighted to be able to relaunch it in the UK and Republic of Ireland.
"It was withdrawn from the market in 2010 when OPK Biotech acquired the assets of manufacturer Biopure Corporation in 2009. But this year, OPK Biotech resumed the manufacture of Oxyglobin and we have stocks available to practices from this month (FEB)."
"Oxyglobin turns around clinical outcomes for dogs with anaemia, regardless of the cause of the condition, which is why it is the objective choice for safety, effectiveness and convenience.
"Oxyglobin is the only oxygen-carrying fluid available off the shelf for dogs in need of oxygen support and no typing or cross-matching of the recipient's blood is required."
Oxyglobin, a sterile formulation of polymerised purified bovine haemoglobin in a balanced salt solution with proven efficacy, is available in single dose 60ml and 125ml infusion bags.
For further information on Oxyglobin, see www.dechra.co.uk
Running in July, the campaign aims to raise awareness of hyperthyroidism in cats and hypothyroidism in dogs, educate pet owners to spot the symptoms and thereby encourage early diagnosis.
MSD Animal Health says it hopes the campaign will increase the number of pets being taken to their veterinary practice for diagnosis, and increase both return visits and treatment compliance.
Practices supporting Pet Thyroid Month will be supplied with resources to help them educate pet owners about the two conditions.
Caroline Darouj, product manager at MSD Animal Health, said: "Although hyperthyroidism in cats and hypothyroidism in dogs are well known conditions and diagnosis is generally straightforward, a large number of vets in Europe state that both disorders are under-diagnosed, due to the fact that pet owners don’t recognise the signs.
"We wanted to launch our Thyroid Month campaign to encourage pet owners to spot the early symptoms of thyroid issues in their pets and seek advice from their veterinary practices.
"Our aim is also to benefit and educate vets and vet nurses with regard to the use of Leventa and Vidalta in treating these manageable conditions in both dogs and cats."
To find out more about Pet Thyroid Month, visit www.vidalta.co.uk
The strange phenomenon was spotted by Veterinary Vision's clinical director Chris Dixon when he examined Dachshund called Margo, which had been referred for the treatment of a corneal ulcer and fungal infection.
Chris said: “I was assessing Margo’s eye and was very surprised to see a face smiling back at me.
"It perhaps doesn't bear quite the same resemblance as the Turin Shroud. Still, I've never seen anything like it before.
"The good news is that it does not appear to have affected her vision at all.”
Apparently the smiling face is still there, even after Chris performed a corneal graft.
Chris added: "I think we can safely say that Margo is a very happy dog, both inside and out!"
MsRCVS Sean Cleary and Richard Thomas, and accountant Jane Platt have opened their first practice, Burford Lane Vets in Cheshire, and now plan to open 10 more practices over the next five years, two in Spring 2022
Burford Lane Vets is headed up by Pieter De Villiers MRCVS, who has become an equity owner, supported by a team of nine vets, nurses and receptionists.
Sean said: “Our vets benefit from our many years of clinical, financial, human resources and procurement experience and have the opportunity to add the finishing touches to a state-of-the-art practice, where no expense has been spared on the fit out and equipment.
"Everything from finding a property, negotiating the lease, fitting out the practice and health and safety is taken care of.
"It means our equity partners can enjoy being fantastic vets and reap the financial rewards that brings, and we are here to support the practice and take care of all the administration, procurement, marketing and everything else that goes into running a successful business."
Sean added: “We have benefited from the shift in the industry that saw veterinary groups acquired by large corporate businesses.
"However, this has inadvertently made it difficult for the next generation of vets to follow the traditional route of buying into a practice as they progress from a junior role to partner, as corporate interest has pushed the values of practices to unaffordable levels for most vets.
"We want to bridge that gap and give a leg up to vets who want to be masters of their own destinies, without the difficulty of starting from scratch or having to find a huge initial investment.”
Sean says he thinks there are a great many vets who would like to launch their own practice.
However, starting from scratch is fraught with risk, expense, and complexity.
Sean added: “Our innovative model helps great vets set up in business as leaders of their own practice and our unique offering is already attracting interest from high-calibre individuals.
"We would encourage any colleagues out there who feel they would like to join us in our new venture to get in touch via our website.”
Sean concluded: “The business acumen we have built up over our many years of working in the industry enables us to provide practical support, mentorship and guidance for vets through every step of the process, and that’s something we’re passionate about.
"The directors will be working across all practices to provide support whenever it’s needed. We are in it for the long haul, not just the initial set up stage, and we will become a part of every practice that opens.
“We take a real pride in being the solution to fix the broken practice ownership model and North Star Vets will empower ambitious vets to enjoy a better and more successful future, which in turn will translate into the standard of care our clients enjoy.”
For the research1, 190 faecal samples were collected from dogs in 140 households (114 samples from raw fed dogs and 76 from non-raw fed dogs).
Salmonella species was detected in 4% of the samples (all raw fed) and antimicrobial-resistant E. coli was detected in 40% of all dogs, but in 62% of raw fed dogs.
The authors say that statistical analysis confirmed that this represented a significantly higher prevalence of AMR E. coli, including multidrug resistance and third generation cephalosporin resistance, and Salmonella species in dogs fed raw compared to non-raw meat diets.
The authors concluded that strategies should be implemented to increase the awareness of the risks of feeding raw meat diets to dogs, to reduce any potential risk to owners, their families, and their pets.
Nicola Di Girolamo, Editor of JSAP says: “In this study, an association between raw meat diets in dogs and faecal carriage of potentially dangerous enteric bacteria has been observed.
"Readers should keep in mind that cross-sectional studies such as this one lay the basis for additional research more suited to prove causality.”
Idexx has launched Pet Resist (www.petresist.com), an online map of the levels of antibiotic resistance recorded in cats and dogs by the company over the past five years.
The map displays geographical variations in resistance to the top 10 antibiotics used in cats and dogs.
Simon Wootton, UK CAG Marketing Manager from Idexx said: "The ability to select the most appropriate antibiotic prior to testing may increase the effectiveness of treatments and reduce the number of return visits. We believe that this new service will also help prolong the effective life of existing antibiotics at a time when there is considerable pressure on the profession to reduce their use."
Pet Resist shows levels of resistance overlaid on an interactive UK map down to individual postcode areas. You enter the postcode, the antibiotic (amoxicillin, ampicillin, cefaliexn, etc) and the suspected organism (E coli, S aureus, etc), after which you'll be able to see the level of resistance based on historical data from the past five years, and use this to help choose appropriate therapies.
Simon added: "We have used results of MIC tests on over 200,000 samples submitted to Idexx to develop the database upon which the resistance levels are based. The data will be continually updated as we receive more samples at our Wetherby laboratory, further increasing the accuracy and value of the service to vets and their clients."
Prior to joining Fitzpatrick Referrals, Gerard was a Senior Lecturer in Internal Medicine at the University of Glasgow as well as Head of the Emergency Service and Director of both the Internship and ECVIM Residency Programmes. He is also a European and Royal College Recognised Specialist in Internal Medicine, and recently became one of few specialists in the world to have completed a 12 month Fellowship in Interventional Radiology at the Animal Medical Center in New York.
Gerard said: "When I returned to the UK, it was a natural fit for me to join Fitzpatrick Referrals. The team all share the same ethos and together I know we will be able to offer a truly world-class service to our patients and their family. I genuinely believe we will be able to change what is accepted as the gold standard of care for animals in the UK."
Fitzpatrick Referrals says its interventional radiology service performs minimally invasive procedures that are often considered the standard of care in human medicine, providing options for veterinary patients where conventional therapies are not associated with the best outcome.
Clinical Director of Oncology and Soft Tissue, Professor Nick Bacon said: "Gerard joining the team in Guildford opens new doors for our patients but more importantly we hope the disciplines of veterinary oncology and soft tissue surgery as a whole. He brings huge experience in interventional radiology solutions for portosystemic shunts, tracheal collapse and urinary calculi obstruction. Gerard is also key to developing our cancer care. Progress is not about ever bigger treatments chasing a cure; it can just as easily mean delivering palliative or curative-intent treatments in smarter ways, with less side-effects and lower morbidity. I am looking forward to watching our treatments evolve for a variety of tumours including urinary, liver, lung and head and neck. No cancer treatment is perfect, but we are striving for the best we can for the patient in front of us."
Noel Fitzpatrick said: "It remains my objective to build the greatest team of super-specialists on planet earth where we can offer all of the options to all of the animals and the families that love them all of the time. Gerard has a unique skill set that will not only complement our growing team, but will enhance the spectrum of treatments we can offer and which the families of animals throughout the UK and beyond really want. Increasingly people want the same level of care for their dogs and cats as we have for ourselves and our goal is to deliver exactly that with the very best team and facilities in the world today."
Fitzpatrick Referrals will be holding a Partners in Care CPD session on 25th May inviting vets to meet Dr Gerard McLauchlan and discover more about the interventional radiology service. To register your interest, contact Sarah on SarahC@fitzpatrickreferrals.co.uk.
The RCVS Disciplinary Committee has removed a veterinary surgeon formerly working in Lincolnshire from the Register, after finding him guilty of serious professional misconduct for drink-driving related convictions, failing to inform his employer of these convictions, and driving whilst disqualified.
Jaroslaw Slominski, a former employer of Grants Veterinary Services plc, chose not to attend the three-day hearing. The Committee considered whether to proceed with the case, using criteria identified by the Court of Appeal in R v Jones (Anthony) in 2002 and confirmed by the House of Lords. It concluded it was in the interests of justice that the hearing should go ahead.
The charges related to two convictions Mr Slominski received on 17 March 2010 at Lincoln Magistrates Court: failure to provide a specimen of breath for analysis and driving without due care and attention (after his vehicle collided head-on with another car). Mr Slominski failed to inform his employers of these convictions, as he was contractually obliged to do, and that he was now disqualified from driving.
Having heard evidence from Mr Slominski's line manager, the Committee also found that he had driven his employer's vehicle whilst disqualified, although it could not be sure that he had done so on all the occasions alleged. Therefore, the Committee did not go on to consider an alternative part of the charge - that Mr Slominski had dishonestly claimed money from his employer by falsely submitting expenses claims.
Disciplinary Committee Chairman Prof Peter Lees said: "The combination of factors in this case, namely, the serious nature of his conviction in failing to provide a specimen of breath, his subsequent premeditated conduct in not informing his employers and driving whilst disqualified should be treated by the profession very seriously. The Committee has concluded that the combination of the conviction and the conduct is incompatible with Mr Slominski practising as a veterinary surgeon."
The Committee directed that Mr Slominski's name be removed from the Register.
The awards, comprising academic book vouchers, were presented at the University’s RCVS ceremony after graduation earlier this month.
Jamie Rahman BVSc won the award for the most engaged veterinary student on EMS placement. Feedback about his placement included: 'Exceptional attitude'. 'Contributed actively to good clinical discussion'. 'Intelligent and engaging’. 'Shows true dedication to learning as much as he can whilst in practice, trying to spend as much time with the different specialists as possible'.
Meanwhile, Cheviot Vets in Alnwick won the students' award for outstanding clinical EMS placement 2019. Comments received from students included: ‘I would not be nearly as prepared and ready for practice without the support and training of the team at Cheviot Vets.’ ‘They invested an incredible amount of time into helping me develop my husbandry knowledge and skills.’ ‘Really supportive manner and encouraged me to develop my skills.’
Sarah Heming, Director of Public Affairs and Customer Relations at Zoetis said: "Zoetis has a high focus on supporting the professional advancement of the veterinary profession. We are proud sponsors of the EMS Recognition Awards for Bristol University alongside other initiatives such as the Young Vet of the Year Awards in partnership with the British Veterinary Association.
"The initial stages of a veterinary career are pivotal so helping winning individuals to invest in academic or professional resources to support their continued development in practice can be very beneficial. We would also like to formally thank the winning practices for their invaluable commitment and support."
The company says that despite the development of alternatives to natural bone grafting, such as allografts and synthetic products, autologous bone graft is still considered the standard. However, it has a number of disadvantages, such as donor site morbidities and lameness, limited availability of graft volume (particularly in small size pets) and additional surgical time.
Biocera-Vet is a new bone substitute indicated in surgical procedures where bone grafting is necessary, such as arthrodesis, complex fractures, corrective osteotomy used in correction of limb deformities or as add-on to Tibial Tuberosity Advancement (TTA).
Biocera-Vet is an injectable synthetic self-hardening calcium-phosphate cement combining osteo-inductive, osteo-conductive and osteo-integrative properties designed to support a fast and strong consolidation.
TheraVet says Biocera-Vet also presents an excellent safety profile thanks to its biocompatibility, reduced comorbidities and superior ergonomics which save a significant amount of surgical time.
Dr Olivier Stiévenart, an orthopaedic veterinary surgeon at Surgivet in Belgium said: "Using Biocera-Vet has enabled us to optimise our patient care considerably, by reducing the operating time by at least 30 minutes. The use of an efficient and rapid bone substitute represents a real progress in terms of both operations and the animal’s quality of life".
Julie Schurgers, Chief Commercial Officer of TheraVet, said: "Biocera-Vet is a unique product on the veterinary bone substitute market, combining outstanding bone consolidation properties with an excellent safety profile and superior ergonomics. We are very excited today to announce its commercialisation on the market and are convinced that this innovative product will significantly improve the daily practices of veterinarians, for the well-being of patients and their owners."
The product is now available in Belgium, and will be rolled out in France and the Netherlands shortly, with the rest of Europe following later in 2021 / 2022.
For more information, visit: https://www.thera.vet/en/biocera-vet
During the webinar, which took place earlier this month, senior officers and staff from the College explained the new guidance, what it will mean for the profession, and answered questions submitted by delegates.
The webinar was chaired by RCVS President Dr Melissa Donald MRCVS with a panel comprising Standards Committee Chair Linda Belton MRCVS, RCVS Registrar Eleanor Ferguson, and RCVS Head of Standards Gemma Kingswell.
The webinar included an overview of the main changes, the considerations to take into account when prescribing POM-Vs remotely, the circumstances under which POM-Vs cannot be prescribed remotely, the prescription of antibiotics, antifungals, antiparasitics and antivirals, and how the guidance will be enforced.
Eleanor Ferguson, RCVS Registrar, said: “We have also now published a range of practice-based scenarios to help explain how the new guidance should be followed in various circumstances, and in relation to different species.
"These scenarios cover a variety of different situations, including how the guidance applies to two or more practices with mutual clients, consultancy services and the prescription of long-term controlled drugs.”
A second webinar will be held on Monday 17th July, with priority for those who wanted to attend the June webinar but were not able to do because it was over-subscribed.
www.rcvs.org.uk/undercare
In one case, Tigga, a 17-year-old cat with an itchy and destructive tumour on her nose, was in complete remission within 44 days. In another case, a tumour vanished in a dog where the aim of the treatment was only to shrink the mass before an operation to remove it.
NDSR, which is based in Bletchingley, is the only referral centre in the UK and one of very few in the world offering electrochemotherapy in pets.
Electrochemotherapy is given in two stages.
First, the patient is given a mild dose of intravenous chemotherapy in the normal way and then, using a probe, a precise electrical charge is given to the area on or around the tumour.
This temporarily opens up tiny holes in the cells, big enough to allow the drug to enter, which then close again in microseconds. This means the drug will only attack cancerous cells, unlike normal chemotherapy, which also kills healthy cells.
Gerry Polton, clinical director of oncology at NDSR, said: "Normal chemotherapy works on the principle of being more damaging to cancer than non-cancerous tissue. Some cancers are more resilient, so there are differences in how they respond to treatment, and this can cause more harm to the patient.
"Electrochemotherapy involves clever anatomical targeting of a specific site and is an effective way of protecting healthy cells.
"The results we are seeing in cases like Tigga’s are unprecedented and we are learning about the procedure all the time. We are always looking for better ways of treating cancer without the effect of harming the patient indiscriminately and this has proved to be a very effective way of doing this."
According to NDSR, the results could help inform the development of the targeted treatment in humans, where electrochemotherapy is used in a small number of cases in the NHS.
At present, many clinical trials are carried out on laboratory animals which are bred with no immune system – but dogs have similarities in genetics to humans and have working immune systems, meaning they can provide a more accurate parallel for how the treatment may work in people.
Gerry said: "A pet dog would be a good model for human cancer studies. It's a mammal with a heartbeat, blood supply and working immune system.
"Progress with electrochemotherapy in animals is being made in parallel with progress in electrochemotherapy in the human field, and what we are learning may even inform what is happening in people.
"Electrochemotherapy is a form of treatment which Cancer Research UK describe as 'fairly new' on its website, with limited information about its effectiveness. So maybe something would be gained from learning together."
The survey, which takes about 5 minutes (I timed it), is designed to canvas opinion about the priorities for learning and development.
Rich Casey, Junior Vice President of the VMG (pictured right), said: "From marketing to HR to financial planning and all points in between, today’s veterinary leaders require expertise in every aspect of running a successful business.
"We want to create a truly valuable, constructive and evidence-based CPD calendar for next year. Views from those working in the profession will help us to fully understand what good leadership and management look like in the veterinary world and we will then make sure that the programme promotes best practice in these important areas. We thank everyone who takes the time to complete the survey."
The survey can be accessed here: https://www.surveymonkey.co.uk/r/VETCPDPR
Ceva Animal Health has renamed Tildren, its tiludronate-based bisphosphonate infusion for the treatment of bone spavin in horses, as Equidronate.
Tiludronate has been used to treat bone spavin and navicular disease in Europe for many years and was licensed for bone spavin in the UK in 2008. Ceva says trials published last year show that horses suffering lameness caused by bone spavin can show marked improvement following treatment with an Equidronate infusion, in combination with controlled exercise.
Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints and is considered to be one of the most common forms of hindlimb lameness in the horse. Horses with bone spavin experience abnormal bone remodeling changes. According to the company, Equidronate helps to modulate the osteoclasts to help prevent excessive bone removal and give the osteoblasts a chance to catch up. This in combination with adjusting levels of exercise helps to harmonise the bone adaptation needed for the horse to perform its athletic duties.
In the trials one in four horses showed marked improvement; two in four showed improvement, which, when combined with other treatment, enabled the horse to resume former levels of activity and one in four horses showed no response.
Ceva Animal Health has produced a range of explanatory leaflets for horse owners on bone spavin, navicular disease and sacroiliac disease, as well as a helpful booklet detailing the discharge procedures for horses that have been treated with Equidronate.
For free copies and for further product information contact your Ceva sales representative, ring Ceva on 01494 781510 or visit the website at http://www.ceva.uk.com/
Bayer Animal Health (makers of Advocate, Advantix, Advantage, Seresto, Profender, Drontal and Droncit) has launched 'It's a Jungle Out There', an educational initiative aimed at simplifying parasite control for veterinary practices and pet owners alike.
The impressive-looking initiative comes on the back of research carried out by the company which found:
Dan White, Group Product Manager for Bayer's Animal Health division said: "Our research concluded that many vet practices are missing an opportunity because of a lack of clarity regarding best practice for parasite control. With ongoing support and practical development tools, Bayer's 'It's a Jungle Out There' Programme is an educational initiative which will arm vet practices with the tools they need to make parasite control clearer and more accessible to owners, helping to ensure the UK is a nation of healthy parasite-free pets and happy owners."
Bayer says the first stage of the 'It's a Jungle Out There' initiative aims to help the veterinary community identify opportunities where they can help to improve pet owner compliance. Vet practices will then be supported in developing a parasite protocol which will then be launched to consumers via a heavyweight advertising and PR campaign.
The initiative comprises a new educational website: www.jungleforvets.co.uk, which includes practice development workbooks, market research and trends, extensive technical information on a wide variety of parasites and CPD assessments. Additional downloadable content includes a range of materials such as images, videos, downloads and web buttons.
From the end of August, practice support materials will be available including a waiting room display pack, parasite guide and dispenser, vet nurse reference guide, waiting room posters, lifestyle questionnaire, badges and static window stickers.
The pet owner focus will begin in September and will include an interactive website, advertising and an extensive print and broadcast PR campaign with celebrity ambassadors David Bellamy and TV vet Steve Leonard. This activity is aimed at driving owners towards their vet practice for advice on parasite risks.
A free copy of the compendium has been sent to every veterinary practice in the UK, and it is also available online at: www.noahcompendium.co.uk. A special edition of the book commissioned by AMTRA will also be available for its SQPs shortly.
NOAH chief executive Dawn Howard said: "The NOAH Compendium, in all its formats, remains a major part of NOAH’s efforts to ensure appropriate access and responsible use of medicines for all animals. We are pleased it is even more comprehensive this year, as we continue to expand its list of contributors.
"Every NOAH member, as well as the non-member participants in the NOAH Compendium, is a signatory to the NOAH Code of Practice on Promotion, which demonstrates their commitment to operate above and beyond any regulatory requirements."
She added: “As well as product datasheets, the Compendium includes another vital resource – the contact details for each participating company. Company veterinary and technical advisors have detailed knowledge about their company’s medicines. The NOAH Code includes the requirement for NCAH qualification for NOAH staff in technical dialogue with prescribers and users of animal medicines – meaning their advice can be regarded as a valuable and trusted resource. They are ready to talk to prescribers about the use of a medicine in a particular animal or in a particular situation, as well as to explain any queries about the data sheet."
Veterinary practices that have not yet received a copy, perhaps because they are new or have changed address in the past year should contact NOAH (noah@noah.co.uk).
Extra copies are also available to order, for £47.50. Special prices are also available for bulk orders.
Instead of conducting major open surgery, Chris Shales, an RCVS and European Specialist in Small Animal Surgery, Andrew Kent, a European Specialist in Internal Medicine, and the cardiology team at Willows are using coil embolization, a minimally invasive technique which they say is far safer and less likely to lead to post-operative complications.
The procedure involves threading tiny coils, via the jugular vein, through the venous system and positioning them in the blood vessel that needs to be closed. The coils encourage the blood to form a clot and so, over time, seal the vein.
Chris said: "This procedure of treating intrahepatic portosystemic shunts is associated with a lower risk of mortality and a lower surgical morbidity rate when comparted to open surgery. The overall outcome of the two approaches is similar in terms of reduction of flow through the shunt vessel.
"Access is gained via a small incision in the neck to allow the team to operate on the liver via the jugular vein using fluoroscopy to visualise the placement of a stent within the vena cava and embolization coils within the abnormal vessel.
"Intrahepatic shunts can be extremely challenging for the surgical team to access with the result that standard, open surgical treatment of these abnormal vessels can risk life-threatening complications and animals can require a significant time to recover."
For more information about shunt surgery at Willows, contact Chris Shales or Small Animal Internal Medicine Specialist Andrew Kent on 0121 712 7070 or email enquiries@willows.uk.net.
Photo: Chris Shales, left, with Andrew Kent, centre, and cardiologist Mike Martin ('pass me a gin and tonic, would you').
Protexin has announced that preliminary data from a clinical trial supports the use of Denamarin® to protect against lomustine (CCNU)-induced hepatotoxicity in dogs.
The study is being performed at the University of California-Davis, Veterinary Medical Teaching Hospital, and the initial results were recently presented at the American College of Veterinary Internal Medicine (ACVIM) Annual Forum. Marketed in the UK by Protexin, Denamarin is the combination of S-adenosylmethionine (SAMe) and silybin.
According to the company, most dogs treated with the chemotherapeutic agent CCNU experience liver enzyme elevation. Elevation of certain liver enzymes such as alanine transferase (ALT) is a key indicator of liver trauma; significant enzyme elevation may lead to a discontinuation, delay, or reduction in chemotherapy. The ongoing clinical trial was designed to evaluate Denamarin as a hepatoprotectant in dogs diagnosed with neoplasia that are undergoing CCNU therapy.
The trial consists of two groups of randomly assigned dogs. Dogs in Group 1 receive Denamarin beginning at the start of CCNU therapy. Group 2 dogs do not receive Denamarin unless they develop a Grade IV hepatotoxicity.
Results of a planned interim analysis completed on the first 30 dogs enrolled revealed that starting Denamarin when CCNU therapy was instituted (Group 1 dogs) appeared to provide hepatoprotection. While the mean post-therapy ALT elevation for Group 1 was 119 IU/L (p=0.1), for Group 2 dogs, the post-therapy ALT level was 815 IU/L (p=0.046). Chemotherapy was altered due to elevated liver enzymes in three Group 2 dogs but only one dog in Group 1.
Janine Barlow, Technical Manager at Protexin said: "We are extremely pleased by the initial findings of this research. The use of Denamarin with chemotherapy looks to help protect liver function allowing for successful completion of therapy and hopefully a longer, happier life for the pet. We look forward to the results of the full study."
Protexin says the SAMe and silybin in Denamarin support and maintain hepatic function by mechanisms including increasing levels of glutathione, the liver's main detoxifying agent; promoting protein synthesis; and stimulating bile flow. Denamarin is useful as part of a polymodal approach to the management of liver health.
Denamarin is available for both dogs and cats in an enteric-coated tablet.
Freelance Surgical says electrosurgery has yet to take off in the veterinary profession in the way that it has in human surgery because many veterinary surgeons are still unfamiliar with the technology and have concerns about safety.
In fact, the company says, it can make surgery more efficient, faster and safer.
In the new series of videos, Alasdair Hotston Moore covers the background of electrosurgery, an overview of the Gima Diathermy unit and a practical demonstration of how to use the equipment correctly and safely.
Bilitis Hammond, Veterinary Specialist at Freelance Surgical said: “With the GIMA electrocautery units being so popular, we were surprised to find there was very little training on best use available online.
"We wanted to offer some short bitesize videos that show surgeons what this machine can offer so they are using it to its full potential and safely.
"We feel these videos will be a huge asset to everyone in practice. “
https://www.youtube.com/channel/UCfKRtTQ2EA16cP-gfkqSVdA
https://www.freelance-veterinary.co.uk/surgery/electrosurgery